GAMMA Investing LLC Acquires 94,464 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

GAMMA Investing LLC boosted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 17,558.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,002 shares of the specialty pharmaceutical company's stock after purchasing an additional 94,464 shares during the quarter. GAMMA Investing LLC owned about 0.44% of ANI Pharmaceuticals worth $6,360,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE grew its holdings in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after acquiring an additional 531 shares in the last quarter. KBC Group NV increased its holdings in shares of ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after purchasing an additional 600 shares during the period. KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals during the fourth quarter valued at $166,000. Rafferty Asset Management LLC acquired a new stake in ANI Pharmaceuticals during the fourth quarter worth about $200,000. Finally, Bridgefront Capital LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $204,000. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Up 0.6%

NASDAQ:ANIP traded up $0.41 during trading hours on Wednesday, hitting $63.28. 12,427 shares of the stock traded hands, compared to its average volume of 329,036. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -115.05 and a beta of 0.55. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $77.00. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a 50 day moving average price of $64.94 and a 200 day moving average price of $61.01.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.33. The firm had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company's revenue for the quarter was up 43.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.82 EPS. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ANIP shares. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target for the company. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective on the stock. Guggenheim reiterated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research note on Monday, April 21st. Finally, Wall Street Zen downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $80.13.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 881 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the transaction, the senior vice president now directly owns 89,897 shares of the company's stock, valued at approximately $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the transaction, the vice president now directly owns 80,145 shares of the company's stock, valued at approximately $5,526,799.20. The trade was a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,681 shares of company stock valued at $347,638 in the last three months. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.